Citation: | Bingjia Zhao, Qian Zhang, Yiqian He, Weifang Cao, Wei Song, Xiaochun Liang. Targeted metabolomics reveals the aberrant energy status in diabetic peripheral neuropathy and the neuroprotective mechanism of traditional Chinese medicine JinMaiTong[J]. Journal of Pharmaceutical Analysis, 2024, 14(2): 225-243. doi: 10.1016/j.jpha.2023.09.007 |
[1] |
M.A. Elafros, H. Andersen, D.L. Bennett, et al., Towards prevention of diabetic peripheral neuropathy: Clinical presentation, pathogenesis, and new treatments, Lancet Neurol. 21 (2022) 922-936.
|
[2] |
D. Selvarajah, D. Kar, K. Khunti, et al., Diabetic peripheral neuropathy: Advances in diagnosis and strategies for screening and early intervention, Lancet Diabetes Endocrinol. 7 (2019) 938-948.
|
[3] |
E.L. Feldman, K.A. Nave, T.S. Jensen, et al., New horizons in diabetic neuropathy: Mechanisms, bioenergetics, and pain, Neuron 93 (2017) 1296-1313.
|
[4] |
A. Sadosky, J. Mardekian, B. Parsons, et al., Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy, J. Diabetes Complications 29 (2015) 212-217.
|
[5] |
H. Tang, A. Jiang, J. Ma, et al., Understanding the signaling pathways related to the mechanism and treatment of diabetic peripheral neuropathy, Endocrinology 160 (2019) 2119-2127.
|
[6] |
P. Fernyhough, Mitochondrial dysfunction in diabetic neuropathy: A series of unfortunate metabolic events, Curr. Diabetes Rep. 15 (2015), 89.
|
[7] |
S.K. Roy Chowdhury, D.R. Smith, A. Saleh, et al., Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes, Brain 135 (2012) 1751-1766.
|
[8] |
Y.V. Madhavi, N. Gaikwad, V.G. Yerra, et al., Targeting AMPK in diabetes and diabetic complications: Energy homeostasis, autophagy and mitochondrial health, Curr. Med. Chem. 26 (2019) 5207-5229.
|
[9] |
B.L. Tang, Glucose, glycolysis, and neurodegenerative diseases, J. Cell. Physiol. 235 (2020) 7653-7662.
|
[10] |
A.V. Mathew, M. Jaiswal, L. Ang, et al., Impaired amino acid and TCA metabolism and cardiovascular autonomic neuropathy progression in type 1 diabetes, Diabetes 68 (2019) 2035-2044.
|
[11] |
D.R. Rojas, R. Kuner, N. Agarwal, Metabolomic signature of type 1 diabetes-induced sensory loss and nerve damage in diabetic neuropathy, J. Mol. Med. 97 (2019) 845-854.
|
[12] |
O.J. Freeman, R.D. Unwin, A.W. Dowsey, et al., Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy, Diabetes 65 (2016) 228-238.
|
[13] |
S.K. Chowdhury, D.R. Smith, P. Fernyhough, The role of aberrant mitochondrial bioenergetics in diabetic neuropathy, Neurobiol. Dis. 51 (2013) 56-65.
|
[14] |
S.K. Chowdhury, E. Zherebitskaya, D.R. Smith, et al., Mitochondrial respiratory chain dysfunction in dorsal root ganglia of streptozotocin-induced diabetic rats and its correction by insulin treatment, Diabetes 59 (2010) 1082-1091.
|
[15] |
S. Srinivasan, M. Stevens, J.W. Wiley, Diabetic peripheral neuropathy: Evidence for apoptosis and associated mitochondrial dysfunction, Diabetes 49 (2000) 1932-1938.
|
[16] |
E. Akude, E. Zherebitskaya, S.K. Chowdhury, et al., Diminished superoxide generation is associated with respiratory chain dysfunction and changes in the mitochondrial proteome of sensory neurons from diabetic rats, Diabetes 60 (2011) 288-297.
|
[17] |
L. Zhang, C. Yu, F.E. Vasquez, et al., Hyperglycemia alters the schwann cell mitochondrial proteome and decreases coupled respiration in the absence of superoxide production, J. Proteome Res. 9 (2010) 458-471.
|
[18] |
J. Choi, K. Chandrasekaran, T. Inoue, et al., PGC-1α regulation of mitochondrial degeneration in experimental diabetic neuropathy, Neurobiol. Dis. 64 (2014) 118-130.
|
[19] |
J.D. Panes, A. Wendt, O. Ramirez-Molina, et al., Deciphering the role of PGC-1α in neurological disorders: From mitochondrial dysfunction to synaptic failure, Neural Regen. Res. 17 (2022) 237-245.
|
[20] |
V.G. Yerra, A. Areti, A. Kumar, Adenosine monophosphate-activated protein kinase abates hyperglycaemia-induced neuronal injury in experimental models of diabetic neuropathy: Effects on mitochondrial biogenesis, autophagy and neuroinflammation, Mol. Neurobiol. 54 (2017) 2301-2312.
|
[21] |
V.G. Yerra, A.K. Kalvala, B. Sherkhane, et al., Adenosine monophosphate-activated protein kinase modulation by berberine attenuates mitochondrial deficits and redox imbalance in experimental diabetic neuropathy, Neuropharmacology 131 (2018) 256-270.
|
[22] |
S.K. Chowdhury, R.T. Dobrowsky, P. Fernyhough, Nutrient excess and altered mitochondrial proteome and function contribute to neurodegeneration in diabetes, Mitochondrion 11 (2011) 845-854.
|
[23] |
Q. Yuan, X. Zhang, W. Wei, et al., Lycorine improves peripheral nerve function by promoting Schwann cell autophagy via AMPK pathway activation and MMP9 downregulation in diabetic peripheral neuropathy, Pharmacol. Res. 175 (2022), 105985.
|
[24] |
X. Xu, W. Wang, Z. Wang, et al., DW14006 as a direct AMPKα activator ameliorates diabetic peripheral neuropathy in mice, Diabetes 69 (2020) 1974-1988.
|
[25] |
X. Zhu, Y. Chen, X. Xu, et al., SP6616 as a Kv2.1 inhibitor efficiently ameliorates peripheral neuropathy in diabetic mice, EBioMedicine 61 (2020), 103061.
|
[26] |
X. Liang, L. Cui, S. Guo, Clinical study on Jinmaitong composita on diabetic peripheral neuropathy, Zhongguo Zhong Xi Yi Jie He Za Zhi 19 (1999) 517-519.
|
[27] |
Q. Zhang, W. Song, X. Liang, et al., A metabolic insight into the neuroprotective effect of Jin-Mai-Tong (JMT) decoction on diabetic rats with peripheral neuropathy using untargeted metabolomics strategy, Front. Pharmacol. 11 (2020), 221.
|
[28] |
V. Bril, S. Tomioka, R.A. Buchanan, et al., Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy, Diabet. Med. 26 (2009) 240-246.
|
[29] |
E.L. Feldman, M.J. Stevens, P.K. Thomas, et al., A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy, Diabetes Care 17 (1994) 1281-1289.
|
[30] |
J. Xie, W. Song, X. Liang, et al., Jinmaitong ameliorates diabetic peripheral neuropathy in streptozotocin-induced diabetic rats by modulating gut microbiota and neuregulin 1, Aging 12 (2020) 17436-17458.
|
[31] |
B.L. Furman, Streptozotocin-induced diabetic models in mice and rats, Curr. Protoc. Pharmacol. 70 (2015) 5.47.1-5.47.20.
|
[32] |
Q. Zhang, W. Song, B. Zhao, et al., Quercetin attenuates diabetic peripheral neuropathy by correcting mitochondrial abnormality via activation of AMPK/PGC-1α pathway in vivo and in vitro, Front. Neurosci. 15 (2021), 636172.
|
[33] |
A. Othman, R. Bianchi, I. Alecu, et al., Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats, Diabetes 64 (2015) 1035-1045.
|
[34] |
T. Masuda, Y. Ozono, S. Mikuriya, et al., Dorsal horn neurons release extracellular ATP in a VNUT-dependent manner that underlies neuropathic pain, Nat. Commun. 7 (2016), 12529.
|
[35] |
B. Zhao, Q. Zhang, X. Liang, et al., Quercetin reduces inflammation in a rat model of diabetic peripheral neuropathy by regulating the TLR4/MyD88/NF-κB signalling pathway, Eur. J. Pharmacol. 912 (2021), 174607.
|
[36] |
C. Mollinari, C. De Dominicis, L. Lupacchini, et al., Detection of pathological markers of neurodegenerative diseases following microfluidic direct conversion of patient fibroblasts into neurons, Int. J. Mol. Sci. 23 (2022), 2147.
|
[37] |
W. Song, Y. Sun, X. Liang, et al., Jinmaitong ameliorates diabetes-induced peripheral neuropathy in rats through Wnt/β-catenin signaling pathway, J. Ethnopharmacol. 266 (2021), 113461.
|
[38] |
D.W. Zochodne, H.S. Sun, C. Cheng, et al., Accelerated diabetic neuropathy in axons without neurofilaments, Brain 127 (2004) 2193-2200.
|
[39] |
B. Liu, W. Xin, J. Tan, et al., Myelin sheath structure and regeneration in peripheral nerve injury repair, Proc. Natl. Acad. Sci. U S A 116 (2019) 22347-22352.
|
[40] |
X. Shi, Y. Chen, L. Nadeem, et al., Beneficial effect of TNF-α inhibition on diabetic peripheral neuropathy, J. Neuroinflammation 10 (2013), 69.
|
[41] |
X. Zhang, S. Zhao, Q. Yuan, et al., TXNIP, a novel key factor to cause Schwann cell dysfunction in diabetic peripheral neuropathy, under the regulation of PI3K/Akt pathway inhibition-induced DNMT1 and DNMT3a overexpression, Cell Death Dis. 12 (2021), 642.
|
[42] |
J.H. Koh, Y.W. Kim, D.Y. Seo, et al., Mitochondrial TFAM as a signaling regulator between cellular organelles: A perspective on metabolic diseases, Diabetes Metab. J. 45 (2021) 853-865.
|
[43] |
E. Babetto, K.M. Wong, B. Beirowski, A glycolytic shift in Schwann cells supports injured axons, Nat. Neurosci. 23 (2020) 1215-1228.
|
[44] |
J. Wang, T.T. Christison, K. Misuno, et al., Metabolomic profiling of anionic metabolites in head and neck cancer cells by capillary ion chromatography with Orbitrap mass spectrometry, Anal. Chem. 86 (2014) 5116-5124.
|
[45] |
K. Burgess, D. Creek, P. Dewsbury, et al., Semi-targeted analysis of metabolites using capillary-flow ion chromatography coupled to high-resolution mass spectrometry, Rapid Commun. Mass Spectrom. 25 (2011) 3447-3452.
|
[46] |
D.R. Tomlinson, N.J. Gardiner, Glucose neurotoxicity, Nat. Rev. Neurosci. 9 (2008) 36-45.
|
[47] |
E. Domenech-Estevez, H. Baloui, C. Repond, et al., Distribution of monocarboxylate transporters in the peripheral nervous system suggests putative roles in lactate shuttling and myelination, J. Neurosci. 35 (2015) 4151-4156.
|
[48] |
W.T. Regenold, P. Phatak, C.M. Marano, et al., Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: Implications for the mitochondrial dysfunction hypothesis, Biol. Psychiatry 65 (2009) 489-494.
|
[49] |
T. Behl, A. Gupta, A. Sehgal, et al., A spotlight on underlying the mechanism of AMPK in diabetes complications, Inflamm. Res. 70 (2021) 939-957.
|
[50] |
J. Yang, Y. Wei, T. Zhao, et al., Magnolol effectively ameliorates diabetic peripheral neuropathy in mice, Phytomedicine 107 (2022), 154434.
|
[51] |
B. Beirowski, E. Babetto, J.P. Golden, et al., Metabolic regulator LKB1 is crucial for Schwann cell-mediated axon maintenance, Nat. Neurosci. 17 (2014) 1351-1361.
|
[52] |
Y.C. Chung, J.H. Lim, H.M. Oh, et al., Calcimimetic restores diabetic peripheral neuropathy by ameliorating apoptosis and improving autophagy, Cell Death Dis. 9 (2018), 1163.
|
[53] |
L. Hao, W. Zhong, H. Dong, et al., ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis, Gut 70 (2021) 1933-1945.
|
[54] |
C. Canto, Z. Gerhart-Hines, J.N. Feige, et al., AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity, Nature 458 (2009) 1056-1060.
|
[55] |
K. Chandrasekaran, M. Salimian, S.R. Konduru, et al., Overexpression of Sirtuin 1 protein in neurons prevents and reverses experimental diabetic neuropathy, Brain 142 (2019) 3737-3752.
|
[56] |
V.G. Yerra, A.K. Kalvala, A. Kumar, Isoliquiritigenin reduces oxidative damage and alleviates mitochondrial impairment by SIRT1 activation in experimental diabetic neuropathy, J. Nutr. Biochem. 47 (2017) 41-52.
|
[57] |
N.P. Goncalves, C.B. Vaegter, H. Andersen, et al., Schwann cell interactions with axons and microvessels in diabetic neuropathy, Nat. Rev. Neurol. 13 (2017) 135-147.
|
[58] |
H.L. Seo, S.Y. Baek, E.H. Lee, et al., Liqustri lucidi Fructus inhibits hepatic injury and functions as an antioxidant by activation of AMP-activated protein kinase in vivo and in vitro, Chem. Biol. Interact. 262 (2017) 57-68.
|
[59] |
K. Raafat, M. Wurglics, M. Schubert-Zsilavecz, Prunella vulgaris L. active components and their hypoglycemic and antinociceptive effects in alloxan-induced diabetic mice, Biomed. Pharmacother. 84 (2016) 1008-1018.
|
[60] |
R. Ullah, W. Badshah, G. Ali, et al., Cassia artemisiodes attenuates nociceptive and diabetes-induced neuropathic pain modalities apropos antioxidant and anti-inflammatory mechanisms, Biomed. Pharmacother. 149 (2022), 112834.
|
[61] |
L. Kishore, N. Kaur, R. Singh, Effect of Kaempferol isolated from seeds of Eruca sativa on changes of pain sensitivity in Streptozotocin-induced diabetic neuropathy, Inflammopharmacology 26 (2018) 993-1003.
|
[62] |
A.I. Carballo-Villalobos, M.E. Gonzalez-Trujano, N. Alvarado-Vazquez, et al., Pro-inflammatory cytokines involvement in the hesperidin antihyperalgesic effects at peripheral and central levels in a neuropathic pain model, Inflammopharmacology 25 (2017) 265-269.
|
[63] |
M. Kim, J. Jung, N.Y. Jeong, et al., The natural plant flavonoid apigenin is a strong antioxidant that effectively delays peripheral neurodegenerative processes, Anat. Sci. Int. 94 (2019) 285-294.
|
[64] |
P. Basu, A. Basu, In vitro and in vivo effects of flavonoids on peripheral neuropathic pain, Molecules 25 (2020), 1171.
|
[65] |
J. Chitturi, V. Santhakumar, S.S. Kannurpatti, Beneficial effects of kaempferol after developmental traumatic brain injury is through protection of mitochondrial function, oxidative metabolism, and neural viability, J. Neurotrauma 36 (2019) 1264-1278.
|
[66] |
Z. Xu, X. Chen, X. Jin, et al., SILAC-based proteomic analysis reveals that salidroside antagonizes cobalt chloride-induced hypoxic effects by restoring the tricarboxylic acid cycle in cardiomyocytes, J. Proteomics 130 (2016) 211-220.
|
[67] |
S. Takahashi, K. Saito, X. Li, et al., iTRAQ-based quantitative proteomics reveals the energy metabolism alterations induced by chlorogenic acid in HepG2 cells, Nutrients 14 (2022), 1676.
|
[68] |
S. Fu, R. Cheng, Z. Deng, et al., Qualitative analysis of chemical components in Lianhua Qingwen capsule by HPLC-Q Exactive-Orbitrap-MS coupled with GC-MS, J. Pharm. Anal. 11 (2021) 709-716.
|
[69] |
X. Jiang, Y. Lin, Y. Wu, et al., Identification of potential anti-pneumonia pharmacological components of Glycyrrhizae Radix et Rhizoma after the treatment with Gan An He Ji oral liquid, J. Pharm. Anal. 12 (2022) 839-851.
|